We solve biological problems by working at the molecular scale. Historically, the types of problems we work on generally fall into the following categories: biopharmaceutical cell line development, process development, product characterization, proteomics and genomics, applied synthetic biology, stem cells, and neurodegeneration. Currently, we are working on the following:
- Developing technologies to enhance production and characterization of biopharmaceuticals including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and adeno-associated viral vectors (AAV).
- Establishing industrially relevant platform cell lines and bioprocesses that can be accessible to the broad community.
- Developing methods for protein identification and quantification in complex samples using mass spectrometry.
Our research team is an enthusiastic group of graduate students, postdoctoral scientists, research associates, professional laboratory staff, and undergraduate students. We meet regularly as a group and disseminate our findings at a number of international conferences (American Chemical Society BIOT Division, Cell Culture Engineering, ESACT, ASMS, and others). We are active members in the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) sponsored by the National Science Foundation. We are always looking for bright, motivated new people to join our team.
Our research laboratories are located at the Ammon Pinizzotto Biopharmaceutical Innovation Center on the University of Delaware STAR Campus. Our research infrastructure includes access to state of the art equipment for molecular biology, cell culture, and proteomics. We also regularly use bio-imaging, high-throughput DNA sequencing, and high performance computing cluster resources available through the University of Delaware core facilities. We have ongoing collaborations with numerous corporate partners, clinicians, and academics on-campus and around the world.
Over the years we have been fortunate enough to benefit from a wide variety of sources of financial support including Federal agencies (NIH, NSF, USDA, and NIST), State governments (DE, NY), private foundations, individual donors, and companies. In addition, Prof. Lee leads NIIMBL which is generously supported by the NIST.
We are located at the University of Delaware Department of Chemical and Biomolecular Engineering in the Ammon Pinizzotto Biopharmaceutical Innovation Center on University of Delaware STAR Campus (590 Avenue 1743, Newark, DE 19713).